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IntrOductIOn
Escherichia coli (E. coli) is an opportunist pathogen in the human 
intestinal tract. When this bacterium enters into unnatural sites, 
it can cause a variety of infections, for example UTI, sepsis, 
pyelonephritis, etc. Serotypes that lead to UTIs are designated 
as uropathogenic E. coli. Due to the high rate of morbidity and 
mortality of UTIs, the topic of uropathogenic E.coli is attracting 
lots of attention [1]. E. coli is the most common cause of UTIs, 
accounting for about 85% of community-acquired and 50% of 
hospital-acquired infections. One of the most common infectious 
diseases, out of community and hospital-acquired infections, is UTI, 
resulting in high rates of mortality and morbidity, and consequently 
high economic costs are associated with its treatment [2-4].
β-lactam antimicrobial agents, especially extended-spectrum 
cephalosporins, carbapenems and fluoroquinolones are the prin-
cipal therapeutic choices for the treatment of Enterobacteriaceae 
infections. The rate of bacterial resistance to these antimicrobial 
agents is to rise worldwide [5]. Among the bacterial resistance 
mechanisms, production of Extended-Spectrum β-Lactamases 
(ESBLs) is the most common mechanism of bacterial resistance. 
These enzymes are multitudinous and mutate incessantly in 
response to the high use of antibiotic drugs, resulting in ESBLs [6]. 
Due to ESBL producers, therapeutic choices for infections have 
also become increasingly limited [7].
E. coli and Klebsiella pneumonia are among the most common 
Enterobacteriaceae, involving in both community and hospital-
acquired infections. These bacteria become increasingly resistant 
to expanded-spectrum cephalosporins via production of various 
ESBLs [8,9]. Among all β-lactam antibiotics, carbapenems are 
still the drug of choice for serious infections with ESBL-producing 
Enterobacteriaceae [10].
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ABStrAct
Introduction: Extended-spectrum β-lactamases (ESBLs) are 
a set of plasmid-borne, various and quickly evolving enzymes 
that are a main therapeutic issue now-a-days for inpatient and 
outpatient treatment.
Aim:  The  aim  of  this study was to determine multi-drug 
resistance  (MDR) and ESBLs producing E. coli strains, 
prevalence of class D Carbapenemases among ESBLs 
producing Escherichia coli isolates from educational hospitals 
in Shahrekord, Iran.
Materials and Methods: Uropathogenic Escherichia coli strains 
were isolated from patients with Urinary Tract Infections (UTIs). 
The agar disc diffusion test was used to characterize the 
antimicrobial sensitivity of the E. coli isolates. The ESBL positive 
strains were identified by phenotypic double-disk synergy test, 
by third-generation cephalosporin in combination with or without 
clavulanic acid.  Multiplex  PCR  was  carried out  for  detection 
of  the  three  families  of  OXA-type  carbapenamases  including 
OXA-23,  OXA-24,  and  OXA-48  in  E. coli strains.
results: All bacterial isolates were susceptible to meropenem. 
Ninety isolates produced ESBL, 55 E. coli isolates from inpatients, 
and 35 isolates from outpatients, with a significant association 
(p< 0.05). The prevalence of OXA-23, OXA-24, and OXA-48 in 
the ESBLs producing isolates was respectively 21%, 18%, and 
11% for inpatients, and 10%, 8%, and 6% for outpatients.
conclusion: ESBL-producing E. coli isolates are also a major 
threat in the clinical setting. The findings of this study indicated 
the high occurrence of ESBLs and multiple antibiotic resistance 
in E. coli isolates. 
Nevertheless, resistance to carbapenem can be caused by 
several mechanisms including production of enzymes such as 
carbapenemases Class A KPCs, Class B metallo β-lactamases 
IMP, VIM, NDM, or Class D OXA-type enzymes such as OXA-
23, OXA-24, and OXA-48 [11,12]. Class D β-lactamases or 
oxacillinases are widely distributed among clinically relevant 
gram-negative species. OXA-48 shows a hydrolysis profile that 
includes penicillins, carbapenems and cephalosporins [13]. OXA-
24 and OXA-23 are a class D β-lactamase with carbapenem-
hydrolyzing activity that commonly isolated from a multi-drug 
resistant Acinetobacterbaumannii [14,15]. Carbapenemases class 
D such as OXA-23, OXA-24, and OXA-48 are always associated 
with low levels of resistance to carbapenems such as meropenem, 
imipenem and doripenem [16]. 
AIM
The aim of this study was to determine the multi-drug resistance 
(MDR) and ESBLs pro ducing E. coli strains, prevalence of class 
D carbapenemases among ESBLs producing Escherichia coli 
isolates from educational hospitals in Shahrekord, Iran.
MAterIAlS And MethOdS
clinical Isolates
As E. coli is the most important causative agent of UTIs in both 
inpatients and outpatients [17]. In this study, E. coli strains isolated 
from UTI samples, including inpatients and outpatient, were 
examined. The isolates were collected from September 2013 to 
July 2014 in educational hospitals in Shahrekord, Iran.
Bacterial Identification and Susceptibility testing
Uropathogenic E. coli isolates were characterized through culture 
on respective mediums such as MacCo nkey agar, Blood agar 
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p-values smaller than 0.05. We analysed the data with Statistical 
Package for the Social Sciences software for Windows Version 
18.0 (SPSS, Inc., Chicago, IL, USA).
reSultS
Antimicrobial drug Susceptibility
During a 10-month period, 200 E. coli strains were isolated from 
UTIs of 100 from inpatients and 100 from outpatients. Although 
the resistance to antibiotic in isolated E. coli in outpatient urinary 
infection was remarkably lower than inpatient samples, this 
relationship was only significant for Ceftazidime (p<0.05) [Table/
Fig-2]. Isolated MDR of the outpatients was 39% and of the 
inpatients was 60%. The results of statistical analysis by Chi-
Square test showed that there was a significant relationship 
between the number of isolates that were resistant to multiple-
drug in two groups of inpatients and outpatients isolates 
(p=0.005). Nine antimicrobial agents are tested for all E. coli 
isolates and the obtained data are summarized in [Table/Fig-3].
Prevalence of eSBl-producing E. coli Isolates
Out of 100 E. coli isolates from inpatients UTI, 60 isolates were 
multiple-drug resistant and 55 isolates were ESBL positive. 
Moreover, out of 100 E. coli isolates from outpatient UTI, 39 
isolates were multiple-drug resistance and 35 were ESBL positive. 
DDST was applied to detect ESBL in E. coli isolates that were 
resistant to Ceftazidime using ceftazidime alone or with clavulanic 
acid. Of these, 55 (55%) isolates of inpatient and 35(35%) of 
outpatient were positive for production of ESBL. Statistical analysis 
suggested that there was a significant relationship between ESBL-
borne bacteria in outpatient and inpatient isolates (p=0.007). In 
this study, the prevalence of bacteria producing ESBLs in inpatient 
and outpatient isolates was 55% and 35%, respectively. 
carbapenemases Genes detected
Multiplex PCR was applied to detect the presence of Class D 
carbapenemase genes, including blaOXA-23, blaOXA-24, and blaOXA-48 
in E. coli isolates from inpatients and outpatient UTIs. The PCR 
products of 501 bp blaOXA-23, 249 bp blaOXA-24, and 307 bp blaOXA-48 
and Eosin Methylene Blue agar (Hi Media, India), and biochemical 
tests. After incubation of plates at 35°C for 24 h, the pure isolates 
were identified by biochemical tests such as oxidative, catalase, 
citrate utilization, indole production, triple sugar iron agar, Voges-
Proskauer and methyl red, as described in standard bacteriological 
methods. Antimicrobial susceptibility testing was performed 
by the Kirby–Bauer method in accordance with the Clinical 
and Laboratory Standards Institute (CLSI) recommendations. 
The antibiotic discs used in this study were amikacin 30 μg, 
ciprofloxacin 5 μg, nitrofurantoin 300 μg, norfloxacin10μg, 
Trimethoprim-sulfamethoxazole (1.25/23.75 μg), nalidixic acid 
30 μg, gentamicin 10μg, ceftazidime 30μg, and meropenem 10 
μg (MAST Co., England). The protocol for antibiotic susceptibility 
test has been explained in the CLSI. The diameters of the 
inhibition zone were assessed and the isolates were classified as 
susceptible, intermediate, and resistant categories according to 
CLSI criteria [18]. The MDR bacteria were resistant to three or 
more antimicrobial classes [19].
Phenotypic eSBl detection
ESBLs production was examined for the isolates that were 
resistant to one or more third generation cephalosporins (3GCs) 
by DDST using ceftazidime (30) and ceftazidime/clavulanic acid 
(30/10) (MAST Co. UK). A higher than or equal to 5 mm increase 
in diameter of the inhibition zone of the cephalosporin-plus-
clavulanate disc, when compared to the cephalospo rin only disc, 
was interpreted as phenotypic evidence of ESBLs production. K. 
pneumoniae ATCC 700603 and E. coli ATCC 25922 were used as 
positive and negative controls, respectively. 
Preparation of dnA template for Pcr
Since most ESBL genes are plasmid borne, plasmid DNA was 
extracted and purified using the GeNet bio Plasmid kit (Plasmid 
DNA Isolation Kit, Korea). Plasmid DNA from these microorganisms 
was extracted from overnight bacterial growth in 5 ml Luria Bertani 
medium at 35±2˚C. The GeNet bio Plasmid kit protocol was used 
for bacterial plasmid isolation. Plasmid DNA concentrations 
were determined by the Nano Drop Spectrophotometer (Thermo 
Scientific, USA).
detection of OXA-type carbapenamases encoding 
Genes
All ESBL-producing E. coli isolates were screened by Multiplex 
PCR for the following β-lactamase encoding genes. Multiplex PCR 
was conducted for detection of the three families of OXA-type 
carbapenamases found in E.coli. Sequences of primers for the 
detection of gene encodings blaOXA-23, blaOXA-24, and blaOXA-48 genes 
are given in [Table/Fig-1].
We also utilized the 16S rRNA gene as an internal control. The 
Multiplex PCR conditions are as follows: Initial denaturation at 
95°C for 5 min, 35 cycles of 94 °C for 30 s, 56°C for 40 s and 
72°C for 40 s, followed by a final extension step at 72°C for 
5 min.
ethical consideration
Ethical issues (Including plagiarism, informed consent, misconduct, 
data fabrication and/or falsification, double publication and/or 
submission, redundancy, etc.) have been completely observed by 
the authors.
StAtIStIcAl AnAlySIS
We  compared the differences in susceptibility or resistance between 
the outpatient and inpatient with use of correlations between 
nominal variables. The data were assessed for significance by the 
Pearson Chi-square test or Fisher’s-exact test. The differences 
between groups were considered significantly different with 
[table/Fig-1]: Multiplex PCR for detection of the class D carbapenemase; blaOXA-
23, blaOXA-24 and blaOXA-48. Lane M, DNA size marker (bp); lane P, positive 
control (KlebsiellaPneumoniae ATCC 700603); Lane numbers 1 and 4 are showed 
a 501bp fragment of OXA-23 gene; Lane numbers 2,4 and 5 are showed a 249bp 
fragment of OXA-24 gene. Lane numbers 3 and 5 are shown a 307bp fragment of 
OXA-48 gene. All lane numbers are shown a 420bp fragment of 16SrRNA gene
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oXa   no. of 
isolates 
no. (%) of isolates resistant to: type genes oXa type/total
Cipa aKb Cazc gend fMe SXtf MeMg
inpatient
OXA-23 21/(100) 11(52.3) 8(38) 14(66.6) 6(28.5) 3(14.2) 16(76.1) 0(0)
OXA-24 18/(100) 8(44.4) 7(38.8) 10(55.5) 4(22.2) 3(16.6) 13(72.2) 0(0)
OXA-48 11/(100) 4(36.3) 3(27.2) 8(72.7) 5(45.4) 5(45.4) 9(81.8) 0(0)
outpatient
OXA-23 10/(100) 4(40) 3(30) 7(70) 4(40) 1(10) 7(70) (0)
OXA-24 8/(100) 2(25) 3(37.5) 4(50) 3(37.5) 1(12.5) 6(75) (0)
OXA-48 6/(100) 2(33.3) 2(33.3) 3(50) 2(33.3) 1(16.6) 4(66.6) (0)
[table/Fig-5]: Antimicrobial susceptibility data of E. coli isolates producing OXA-type 
carbapenamases.
a CIP, Ciprofloxacin; b AK, Amikacin; c CAZ, Ceftazidime; d GEN, Gentamicin; e FM, Nitrofurantoin; f 
SXT, Trimethoprim-Sulfamethoxazole; g MEM, Meropenem
In inpatients E. coli isolates, the blaOXA-23 gene was detected in 21 
(21%). Only 18 isolates (18%) carried blaOXA-24, and only 11 isolates 
(11%) carried blaOXA-48. In addition, in outpatients E. coli isolates, 
10 isolates (10%) were positive for the blaOXA-23 gene, 8 (8%) were 
positive for the blaOXA-24, and 6 (6%) were positive for the blaOXA-
48 gene. The 16S rRNA gene was observed in all clinical strains. 
Antimicrobial susceptibility data of E. coli isolates producing OXA-
type ESBLs are summarized in [Table/Fig-5].
dIScuSSIOn
The issue of elevated bacterial resistance to antimicrobial agents 
and treatment of infectious diseases caused by these bacteria is a 
public health problem. In addition, the rate of bacterial resistance 
varies  worldwide, nationwide and even among various geographical 
areas of a country [20]. In our study, all bacterial isolates were 
susceptible to meropenem. In a study by Gorgec et al., in Turkey, all 
the extended-spectrum beta-lactamase producing nosocomial E. 
coli isolates was susceptible to meropenem [21]. Besides, similar 
sensitive pattern were found in China and Nigeria [22,23]. Because 
of stability issues encountered with some imipenem samples in 
gram negative bacteria, imipenem was replaced by meropenem in 
2006 [24]. In the obtained results by disc diffusion method, E.coli 
isolated from urinary infections in inpatients and outpatients have 
shown the highest resistance to trimethoprim-sulfametoxazole 
(73.5) antibiotics and nalidixic acid (58.5%). Other studies also 
showed the highest resistance to trimethoprim-sulfametoxazole 
and nalidixic acid [25,26] in E. coli samples collected from patients 
with UTIs.
In the obtained results by disc diffusion method, E.coli isolated 
from urinary infections in inpatients and outpatients have shown 
the highest resistance to Trimethoprim-sulfametoxazole antibiotics 
and nalidixic acid. In a study in Tehran, Iran Soltan Dallal et 
al., revealed a similar anti-bio gram pattern for trimethoprim-
sulfamethoxazole (80.5%), nalidixic acid (74%), ceftazidime 
(55.5%), and ciprofloxacin (55.5%) for 200 clinical isolates of E. 
coli. They also found that 70% of isolates were multi-drug resistant 
phenotype [25]. 
Other studies also showed the highest resistance to trimethoprim-
sulfametoxazole and nalidixic acid  [26,27] in E. coli samples 
collected from patients with UTIs [28,29]. But this pattern of 
resistance have been different in studies investigating drug 
resistance in strains of ESBL-producing E. coli compared to 
those study working upon the third generation of cephalosporins. 
For example, in a study by Gholiour et al., the level of antibiotic 
resistence for most studied antibiotics was lower than that of 
the present study. for example in a study that was performed by 
Gholipour et al., in Isfahan, Iran, the level of antibiotic resistance 
for most studied antibiotics was lower than that of the present 
study [26]. 
During treatment of UTIs, whenever resistance to routinely 
used antibacterial happens, specific cephalosporins can be 
used for UTIs as alternatives [27]. But ESBL production rate by 
Enterobac teriaceae has increased considerably, which is the 
main problem with use of these cephalosporins [28]. Moreover, 
during recrudescent UTI, the carbapenem-resistant strains appear 
after long-term treatment with meropenem and imipenem. Since 
carbapenem antibiotics are often the drugs of choice for therapy 
of severe infections resulting from ESBL-producing E. coli, the 
incidence of carbapenem resistant E. coli is disturbing [29]. In the 
present study, the rate of antibiotic resistance in inpatient isolates 
was higher than outpatient, that is consistent with other studies 
[30].
It can be inferred that further resistance of strains in hospital was 
due to greater consumption of antibiotics and antiseptics in hospital 
environments, resulting in higher levels of antibiotic resistant strains 
of hospital origin in outpatient’s comparing to inpatients.
primer name Sequence (5' to 3')                      Size(bp)  references 
OXA-23 F GATCGGATTGGAGAACCAGA             501       [20]
OXA-23 R ATTTCTGACCGCATTTCCAT
OXA-24 F GGTTAGTTGGCCCCCTTAAA              249       [20]
OXA-24 R AGTTGAGCGAAAAGGGGATT
OXA-48 F GCGTGGTTAAGGATGAACAC             307       This study
OXA-48 R CGCTCCGATACGTGTAACTT
16S rRNA F AGGCCTTCGGGTTGTAAAGT          420       This study
16S rRNA R ACCTCCAAGTCGACATCGTT
[table/Fig-2]: Primers used for detection of ESBL-producing E.coli isolates by 
Multiplex-PCR.
antibiotic
inpatients outpatients
p-value
resistance 
(%) 
Sensitive 
(%)
resistance 
(%)
Sensitive 
(%)
AK (30μg )a 30 70 25 75 0.42
CIP (5μg)b 48 52 40 60 0.25
GEN (10μg)c 35 65 28 72 0.24
FM (300μg)d 10 90 7 93 0.42
NOR (10μg)e 45 55 40 60 0.4
SXT (1.25/23.75μg)f 75 25 72 28 0.47
NA (30μg)g 62 38 55 45 0.24
MER (10μg)h 0 100 0 100 -
CTZ (30μg)i 55 45 35 65 0.004
[table/Fig-3]: Antibiotic susceptibility pattern of E. coli in both in patients and 
outpatients. a AK, Amikacin; b CIP, Ciprofloxacin; c GEN, Gentamicin; d FM, Nitrofurantoin; 
e NOR, Norfloxacin; f SXT, Trimethoprim-Sulfamethoxazole; g NA, Nalidixic acid; h MER, 
Meropenem; i CTZ, Ceftazidime.
antimicrobial 
agent
(%)
Susceptible 
no
resistant 
no (%)
drug resistant rates % in groups
in-patient/
outpatient
(p-value)
Mdr/non-
Mdr
(p-value)
eSbls/non-
eSbls
(p-value)
AK (30μg)a 145(72.5) 55(27.5) 30/25(0.42) 42/13(0.001) 48/8(0.001)
CIP (5μg)b 112(56) 88(44) 48/40(0.25) 53/35(0.007) 58/30(0.001)
GEN (10μg)c 137(68.5) 63(31.5) 35/28(0.24) 38/25(0.038) 42/21(0.001)
FM (300μg)d 183(91.5) 17(8.5) 10/7(0.42) 13/4(0.02) 15/2(0.001)
NOR (10μg)e 115(57.5) 85(42.5) 45/40(0.4) 49/36(0.048) 52/33(0.001)
SXT 
(1.25/23.75μg)f
53(26.5) 147(73.5) 75/72(0.47) 82/65(0.003) 67/80(0.78)
NA (30μg)g 83(41.5) 117(58.5) 62/55(0.24) 75/42(0.001) 64/53(0.001)
MER (10μg)h 200(100) 0(0) 0/0(0) 0/0(-) 0/0(-)
CTZ (30μg)i 110(55) 90(45) 55/35(0.004) 81/9(0.001) 95/4(0.001)
[table/Fig-4]: Antimicrobial susceptibility results of 200 E. coli strains and their 
resistant rates in different groups.
a AK, Amikacin; b CIP, Ciprofloxacin; c GEN, Gentamicin; d FM, Nitrofurantoin; e NOR, 
Norfloxacin; f SXT, Trimethoprim-Sulfamethoxazole; g NA, Nalidixic acid; h MER, 
Meropenem; i CTZ, Ceftazidime.
were visualized by 8% polyacrylamide gel electrophoresis [Table/
Fig-4].
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Even some debilitating illnesses such as severe sepsis can also 
cause antibiotic resistant gene transfer of exogenous pathogens 
resistant to susceptible endogenous pathogen during treatment 
with antibiotics that it demands multi-drug treatment against this 
pathogen [31,32].
In this study, the prevalence of ESBLs producing E. coli in out 
patients and inpatients UTI was 35% and 55%, respectively. Based 
on the finding of this study, the prevalence of ESBL producing 
E. coli was higher in inpatient isolates than in outpatient isolates. 
Similarly, researches from other countries demonstrated that the 
prevalence of ESBL-positive bacteria are more common in patients 
who, having a history of hospitalization, than in outpatients [31].
In Isfahan, Iran, a study by Mobasherizadeh et al., revealed 44.1% 
and 21.2% frequency for ESBL positive in E. coli strains isolated 
from inpatients and outpatients isolates [32]. Thus, our results were 
consistent with Mobasherizadeh et al., study and the frequency of 
ESBLs in bacteria isolated from inpatients was higher than that 
of outpatients. This suggests that infection control in hospitals 
could decrease the emergence of ESBL-producing bacteria 
and subsequently reduce the spread into societies.  Various 
frequencies of ESBLs producing E. coli have been reported by 
some previous studies in Iran. In a study in Tehran, Soltan Dallal 
et al., showed that 115 (89.8%) E. coli isolates were identified as 
ESBLs producers [25]. In a study in Iran, Zaniani et al., revealed 
that 43.9% of E. coli was ESBL producers [33]. 
In other countries, several studies have revealed that the 
distribution of ESBLs varies. For instance, in a study in Turkey 
by Bali et al., [34], 42 of 50 E. coli strains (84%) isolated from 
different clinical samples were ESBL positive. The prevalence of 
the organisms in Poland was reported 49.3% in E. coli isolates 
[35]. The prevalence of ESBL-producing bacteria has been on 
the rise, mainly in Asia compared with other regions. Thus, the 
geographical distribution of ESBL-producing bacteria could vary 
among countries and settings [36].
The prevalence of the OXA-23, OXA-24, and OXA-48 in our study 
was 21%, 18% and 11%, respectively for E. coli isolates from 
inpatient and 10%, 8% and 6%, respectively for E. coli isolates 
from outpatient. This difference is significant because the p-value 
of the Chi-Square is P < 0.001 and as mentioned above for ESBLs, 
the frequency of OXA type carbapenemase in bacteria isolated 
from inpatients was higher than that from outpatients. 
In addition, the present study showed that OXA-23 and OXA-24 
and OXA-48 were found more frequently in inpatients isolates, and 
that ESBL-positive bacteria was also more frequent in inpatients. 
In a study in India, the prevalence of OXA-48 gene was 32.6 in E. 
coli isolates, but OXA-23 and OXA-24 genes were not identified 
in the E. coli isolates [37]. These results are comparable to the 
results of other studies that have emphasized the spread of OXA- 
48-producing Enterobacteriaceae worldwide, especially in Europe, 
Africa and East-Central Asia [38,39]. 
In Iran, OXA-type carbapenemases was found more frequently in 
A.baumannii, P.aeruginosa and Enterobacteriaceae especially K. 
pneumonia, but no study has been yet investigated E. coli OXA 
producing isolates and to our knowledge, this is the first report 
of the frequency of OXA-type carbapenemases genes in E. coli 
isolates in Iran. In a study by Sohrabi et al., in Northwest of Iran, 
88.7% of A. baumannii isolates carried blaOXA-23 [40]. In another 
study by Kooti et al., in Iran, 40% of A. baumannii isolates had 
positive results for blaOXA-23-like, 7% for blaOXA-24-like and 
0.5% for blaOXA-58-like [41]. 
cOncluSIOn
It is quite alarming to note that many of the isolates included in this 
study were found as multiple drugs resistant. Antibiotic resistance 
has been appearing as a main issue in the management of inpatients 
and outpatients and increases the costs imposed on patients in 
health care systems. Briefly, the prevalence of ESBL-positive E. 
coli isolates found in this study is of enormous concern that needs 
revision of infection control guidelines such as management of 
antibiotic prescription and traditional laboratory identification of 
ESBL-positive isolates to prevent ESBLs spread.
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